Development of a Premium Quality Plasma-derived IVIg (IQYMUNE^®) Utilizing the Principles of Quality by Design—A Worked-through Case Study

References

1. 1.↵
   1. Pierce L. R.,
   2. Jain N.

   Risks Associated with the Use of Intravenous Immunoglogbulin. Transfus. Med. Rev. 2003, 17 (4), 241–251.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Desborough M. J.,
   2. Miller J.,
   3. Thorpe S. J.,
   4. Murphy M. F.,
   5. Misbah S. A.

   Intravenous Immunoglobulin-induced Haemolysis: a Case Report and Review of the Literature. Transfus. Med. 2014, 24 (4), 219–226.

   OpenUrl
3. 3.↵
   1. Chtourou S.,
   2. Paolantonacci P.,
   3. Schmitthaeuser R.,
   4. Lirochon J.

   Process of a Human Immunoglobulin Preparation for Therapeutic Use. FR 01 06234.
4. 4.↵
   1. Juran J. M.

   Quality Control Handbook; McGraw-Hill: New York, 1951.
5. 5.↵
   CMC Biotech Working Group. A-Mab: A Case Study in Bioprocess Development. www.casss.org. [online] 30 October 2009.
6. 6.↵
   ICH Q8. Pharmaceutical Development (R2).
7. 7.↵
   ICH Q9. Quality Risk Management.
8. 8.↵
   ICH Q10. Pharmaceutical Quality System.
9. 9.↵
   ICH Q11. Development and Manufacture of Drug Substances.
10. 10.↵
    1. Steinbuch M.,
    2. Audran R.

    The Isolation of IgG from Mamalian Sera with the Aid of Caprylic Acid. Ach. Biochem. Biophys. 1969, 134 (2), 279–284.

    OpenUrl
11. 11.↵
    1. Bellac C. L.,
    2. Polatti D.,
    3. Hottiger T.,
    4. Girard P.,
    5. Sänger M.,
    6. Gilgen M.

    Anti-A and Anti-B Haemagglutin Levels in Intravenous Innumoglobulins: Are They on the Rise? A Comparison of Four Different Analysis Methods and Six Products. Biologicals 2014, 42 (1), 57–64.

    OpenUrl
12. 12.↵
    1. Goussen C.,
    2. Simoneau S.,
    3. Bérend S.,
    4. Jehan-Kimmel C.,
    5. Bellon A.,
    6. Ducloux C.,
    7. You B.,
    8. Paolantonacci P.,
    9. Ollivier M.,
    10. Burlot L.,
    11. Chtourou S.,
    12. Flan B.

    Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma. BioDrugs 2017, 31 (3), 251–261.

    OpenUrl
13. 13.↵
    1. Christian C. L.

    Studies of Aggregated y-globulin, Sedimentation, Electrophoretic and Anticomplementary Properties. J. Immunol. 1960, 84–112.
14. 14.↵
    1. Zang XX.,
    2. Sun Y.,
    3. Shen F.,
    4. Wang D.,
    5. Zhou L.,
    6. Wang J.,
    7. Kung E.

    Molecular Structure Alteration of IgG Increases Anticomplementary Activity of Intravenous Immunoglobulins. Acta Pharm. Sinica. 1995, 16 (5), 415–419.

    OpenUrl
15. 15.
    1. Dhainaut F.,
    2. Guillaumat PO.,
    3. Dib H.,
    4. Perret G.,
    5. Sauger A.,
    6. de Coupade C.,
    7. Beaudet M.,
    8. Elzaabi M.,
    9. Mouthon L.

    In Vitro and In Vivo Properties Differ among Liquid Intravenous Immunoglobulin Preparations. Vox Sang. 2013, 104 (2), 115–126.

    OpenUrlCrossRefPubMedWeb of Science